Nu-Med Plus, Inc.
Nu-Med Plus, Inc. (OTCQB: NUMD) is a medical device development company focused on designing, innovating, and commercializing technologies that deliver therapeutic inhaled nitric oxide (NO). Founded in 2011, the company’s core mission is to replace large, expensive pressurized gas canisters with proprietary, cost-effective delivery systems for patient care. Its hardware pipeline includes hospital bedside units, specialized systems for medical clinics and rehabilitation centers, research units, and lightweight, mobile rechargeable devices that allow patients to receive controlled doses of high-purity nitric oxide via face mask or nasal cannula. These systems are engineered to target critical therapeutic needs—including high blood pressure, Chronic Obstructive Pulmonary Disease (COPD), Acute Respiratory Distress Syndrome (ARDS), and other conditions that benefit from vasodilation and increased oxygen delivery to injured or diseased tissue.
Operating as an emerging growth company, Nu-Med Plus targets high-potential, underserved niches across global healthcare systems, hospitals, and ambulatory care facilities. The company’s commercial strategy relies on advancing its proprietary nitric oxide-generating formulations and delivery hardware through the U.S. Food and Drug Administration (FDA) regulatory approval process. While its foundational focus is rooted in medical technology development and intellectual property acquisition, the company actively utilizes equity financing and strategic corporate transactions to support its ongoing research, development, and commercialization requirements.